Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06175832 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study

Study acronym: P-CCROSS
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Steven Weyers, MD, PhD to University Hospital, Ghentv8
  2. Lead sponsor: University Hospital, Ghent to Steven Weyers, MD, PhDv7 Show 7 more changesShow less
    • Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: May 10, 2025 to Dec 31, 2027
    • Study sites: 0 to 1
    • Study completion date: Dec 31, 2025 to Dec 31, 2027
    • Start date changed from estimate of Jan 14, 2025 to Jan 27, 2025
    • Eligibility criteria expanded, about 37 words
    • Collaborators expanded, about 1 word
  3. Start date: Nov 1, 2024 to Jan 14, 2025v6
  4. Start date: Sep 1, 2024 to Nov 1, 2024v5
  5. Start date: Jul 1, 2024 to Sep 1, 2024v4
Show 2 earlier versionsHide 2 earlier versions
  1. Start date: Apr 1, 2024 to Jul 1, 2024v3
  2. Start date: Jan 1, 2024 to Apr 1, 2024v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
P-CCROSS is a randomized, prospective monocentric phase 4 study with a crossover study design. The aim of the study is to compare patient satisfaction (by means of questionnaires) and treatment compliance with IVF treatment with CFA (corifollitropin alfa) and PPOS (Progestin-Primed Ovarian Stimulation) versus conventional IVF treatment with a recombinant FSH/GnRH antagonist. The study will also compare patients undergoing elective fertility preservation versus PGT-A (pre-implantation genetic testing for aneuploidy) patients.The study will have a crossover design so that patients will receive both forms of treatment. The investigators will also compare the endocrine profile and ovarian response of CFA/PPOS versus rFSH/GnRH ovarian stimulation cycles.
Trial Details
NCT Number NCT06175832
Lead Sponsor University Hospital, Ghent
Collaborators: Organon
Conditions
(from sponsor)		 Ovarian Stimulation, Quality of Life, Preimplantation Genetic Testing, Fertility Preservation
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov